UBS AM’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $51.1M | Buy |
225,314
+6,401
| +3% | +$1.14M | 0.01% | 657 |
|
|
2026
Q1 | $37.8M | Buy |
218,913
+9,981
| +5% | +$1.85M | 0.01% | 686 |
|
|
2025
Q4 | $41.7M | Buy |
208,932
+672
| +0.3% | +$122K | 0.01% | 648 |
|
|
2025
Q3 | $32.6M | Sell |
208,260
-75,467
| -27% | -$12M | 0.01% | 684 |
|
|
2025
Q2 | $43M | Buy |
283,727
+37,099
| +15% | +$4.95M | 0.01% | 742 |
|
|
2025
Q1 | $37.1M | Sell |
246,628
-51,622
| -17% | -$8.65M | 0.01% | 751 |
|
|
2024
Q4 | $55.1M | Buy |
298,250
+46,994
| +19% | +$9.05M | 0.01% | 641 |
|
|
2024
Q3 | $49.5M | Sell |
251,256
-14,003
| -5% | -$2.91M | 0.01% | 677 |
|
|
2024
Q2 | $54.8M | Buy |
265,259
+44,573
| +20% | +$10.1M | 0.02% | 598 |
|
|
2024
Q1 | $59.8M | Buy |
220,686
+742
| +0.3% | +$177K | 0.02% | 559 |
|
|
2023
Q4 | $52M | Buy |
219,944
+59,353
| +37% | +$11.7M | 0.02% | 573 |
|
|
2023
Q3 | $31.5M | Buy |
160,591
+15,062
| +10% | +$3.09M | 0.01% | 667 |
|
|
2023
Q2 | $29.4M | Hold |
145,529
| – | – | 0.01% | 686 |
|
|
2023
Q1 | $29.4M | Buy |
145,529
+16,865
| +13% | +$3.82M | 0.01% | 686 |
|
|
2022
Q4 | $28M | Sell |
128,664
-508
| -0.4% | -$111K | 0.01% | 680 |
|
|
2022
Q3 | $25.4M | Sell |
129,172
-6,921
| -5% | -$1.49M | 0.01% | 709 |
|
|
2022
Q2 | $29.1M | Sell |
136,093
-3,186
| -2% | -$778K | 0.02% | 653 |
|
|
2022
Q1 | $39.6M | Sell |
139,279
-3,565
| -2% | -$1.1M | 0.02% | 671 |
|
|
2021
Q4 | $53.8M | Buy |
142,844
+3,839
| +3% | +$1.49M | 0.02% | 638 |
|
|
2021
Q3 | $57.4M | Buy |
139,005
+8,172
| +6% | +$3.39M | 0.02% | 590 |
|
|
2021
Q2 | $48.4M | Buy |
130,833
+49,616
| +61% | +$16.6M | 0.02% | 645 |
|
|
2021
Q1 | $23.5M | Sell |
81,217
-10,479
| -11% | -$2.91M | 0.01% | 818 |
|
|
2020
Q4 | $22.9M | Buy |
91,696
+11,266
| +14% | +$2.68M | 0.01% | 820 |
|
|
2020
Q3 | $18.2M | Sell |
80,430
-76,351
| -49% | -$15.8M | 0.01% | 793 |
|
|
2020
Q2 | $27.3M | Buy |
156,781
+21,620
| +16% | +$3.45M | 0.02% | 646 |
|
|
2020
Q1 | $17.1M | Buy |
135,161
+34,073
| +34% | +$5.11M | 0.01% | 717 |
|
|
2019
Q4 | $15.4M | Sell |
101,088
-34,331
| -25% | -$4.75M | 0.01% | 834 |
|
|
2019
Q3 | $17.9M | Buy |
135,419
+14,765
| +12% | +$1.98M | 0.01% | 790 |
|
|
2019
Q2 | $17.1M | Buy |
120,654
+24,241
| +25% | +$3.29M | 0.01% | 804 |
|
|
2019
Q1 | $14M | Buy |
96,413
+6,822
| +8% | +$896K | 0.01% | 840 |
|
|
2018
Q4 | $10.1M | Sell |
89,591
-2,055
| -2% | -$257K | 0.01% | 870 |
|
|
2018
Q3 | $12.3M | Buy |
91,646
+1,587
| +2% | +$196K | 0.01% | 881 |
|
|
2018
Q2 | $10.1M | Sell |
90,059
-4,568
| -5% | -$494K | 0.01% | 946 |
|
|
2018
Q1 | $10.1M | Sell |
94,627
-224
| -0.2% | -$24.1K | 0.01% | 928 |
|
|
2017
Q4 | $10.4M | Sell |
94,851
-20,764
| -18% | -$2.26M | 0.01% | 916 |
|
|
2017
Q3 | $12.5M | Buy |
115,615
+6,474
| +6% | +$665K | 0.01% | 842 |
|
|
2017
Q2 | $11M | Buy |
109,141
+20,133
| +23% | +$1.85M | 0.01% | 883 |
|
|
2017
Q1 | $8.01M | Buy |
89,008
+228
| +0.3% | +$19.4K | 0.01% | 931 |
|
|
2016
Q4 | $6.76M | Sell |
88,780
-14,984
| -14% | -$1.14M | 0.01% | 937 |
|
|
2016
Q3 | $8.65M | Sell |
103,764
-715
| -0.7% | -$59.9K | 0.01% | 909 |
|
|
2016
Q2 | $8.61M | Sell |
104,479
-70,238
| -40% | -$5.79M | 0.01% | 909 |
|
|
2016
Q1 | $13.3M | Sell |
174,717
-10,116
| -5% | -$749K | 0.02% | 783 |
|
|
2015
Q4 | $14.9M | Sell |
184,833
-6,101
| -3% | -$440K | 0.02% | 766 |
|
|
2015
Q3 | $12.1M | Buy |
190,934
+27,672
| +17% | +$1.99M | 0.01% | 827 |
|
|
2015
Q2 | $11.5M | Sell |
163,262
-2,134
| -1% | -$158K | 0.01% | 855 |
|
|
2015
Q1 | $13.1M | Buy |
165,396
+1,052
| +0.6% | +$77.6K | 0.01% | 809 |
|
|
2014
Q4 | $10.5M | Sell |
164,344
-2,000
| -1% | -$125K | 0.01% | 851 |
|
|
2014
Q3 | $9.94M | Sell |
166,344
-12,782
| -7% | -$731K | 0.01% | 841 |
|
|
2014
Q2 | $9.59M | Buy |
179,126
+151,082
| +539% | +$8.29M | 0.01% | 865 |
|
|
2014
Q1 | $1.69M | Buy |
28,044
+5,300
| +23% | +$309K | ﹤0.01% | 1370 |
|
|
2013
Q4 | $1.21M | Sell |
22,744
-1,900
| -8% | -$95.4K | ﹤0.01% | 1451 |
|
|
2013
Q3 | $1.14M | Hold |
24,644
| – | – | ﹤0.01% | 1448 |
|
|
2013
Q2 | $1.01M | Buy |
+24,644
| New | +$1.06M | ﹤0.01% | 1458 |
|
Other funds holding CRL
AI
UBS AM's CRL Position: Q2 2026 in Review
UBS AM increased its Charles River Laboratories (CRL) stake by 2.9% in Q2 2026, buying an estimated $1.14M and bringing the position to 225,314 shares worth $51.1M. The position accounts for 0.01% of the portfolio, ranked #657.
UBS AM first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $59.8M in Q1 2024. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- UBS AM held 225,314 shares of Charles River Laboratories worth $51.1M as of Q2 2026.
- UBS AM bought 6,401 Charles River Laboratories shares in Q2 2026, an estimated $1.14M.
- Charles River Laboratories made up 0.01% of UBS AM's portfolio in Q2 2026, its #657 holding.
- UBS AM first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- UBS AM's Charles River Laboratories position peaked at $59.8M in Q1 2024.
- 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.